Table 3.
Hazard ratios (95% Confidence interval) for CVD outcomes by exposure to endocrine treatment.
| Outcome | Non-users | Tamoxifen only | AI only | AI/tamoxifen |
|---|---|---|---|---|
|
Heart failure or cardiomyopathy Full cohort - unadjusted Full cohort - adjusted >75 years old - unadjusted >75 years old - adjusted No prior CVD - unadjusted No prior CVD – adjusted |
1 1 1 1 1 1 |
0.87 (0.72–1.07) 0.75 (0.54–1.04) 0.92 (0.71–1.18) 1.06 (0.64–1.77) 0.88 (0.72–1.08) 0.76 (0.55–1.06) |
1.33 (1.10–1.62) 0.82 (0.60–1.13) 1.24 (0.97–1.60) 0.83 (0.50–1.39) 1.32 (1.09–1.61) 0.78 (0.57–1.09) |
1.24 (0.91–1.68) 1.27 (0.81–1.98) 1.40 (0.93–2.10) 2.44 (1.32–4.54) 1.25 (0.92–1.70) 1.26 (0.81–1.98) |
|
Arrythmia Full cohort - unadjusted Full cohort - adjusted >75 years old - unadjusted >75 years old - adjusted No prior CVD - unadjusted No prior CVD - adjusted |
1 1 1 1 1 1 |
0.94 (0.80–1.41) 0.91 (0.73–1.15) 0.81 (0.65–1.02) 0.80 (0.52–1.24) 1.03 (0.85–1.25) 1.12 (0.86–1.46) |
1.35 (1.15–1.59) 1.09 (0.87–1.38) 1.28 (1.03–1.59) 1.20 (0.82–1.75) 1.29 (1.06–1.57) 1.19 (0.90–1.56) |
1.18 (0.92–1.52) 1.19 (0.85–1.66) 0.91 (0.60–1.39) 0.89 (0.46–1.74) 1.23 (0.92–1.63) 1.45 (1.01–2.10) |
|
Acute ischemic heart disease Full cohort unadjusted Full cohort adjusted >75 unadjusted >75 adjusted No prior CVD unadjusted |
1 1 1 1 1 |
0.80 (0.57–1.13) 0.52 (0.28–0.96) 0.96 (0.62–1.47) 0.47 (0.15–1.47) 0.79 (0.55–1.12) |
1.18 (0.86–1.61) 1.25 (0.78–2.00) 1.03 (0.67–1.58) 1.18 (0.51–2.74) 1.16 (0.82–1.62) |
0.94 (0.57–1.56) 0.97 (0.46–2.03) 1.02 (0.50–2.09) 1.13 (0.34–3.83) 0.95 (0.56–1.60) |
|
Ischemic stroke or TIA Full cohort unadjusted Full cohort adjusted >75 unadjusted >75 adjusted No prior CVD unadjusted No prior CVD adjusted |
1 1 1 1 1 1 |
0.84 (0.66–1.08) 0.84 (0.59–1.20) 0.83 (0.59–1.16) 0.67 (0.34–1.34) 0.83 (0.65–1.07) 0.82 (0.57–1.19) |
1.20 (0.95–1.52) 1.14 (0.81–1.61) 1.02 (0.73–1.44) 0.94 (0.51–1.75) 1.17 (0.92–1.49) 1.12 (0.78–1.60) |
1.03 (0.72–1.47) 1.12 (0.70–1.80) 0.86 (0.49–1.51) 0.81 (0.35–1.87) 1.05 (0.73–1.51) 1.12 (0.69–1.82) |
Abbreviations: AI, Aromatase Inhibitor; CVD, Cardiovascular Disease; TIA, Transient Ischemic Attack. Adjustment includes following covariates: Age, side, stage, chemotherapy, Trastuzumab, surgical procedure, radiation therapy, CCI, marital status and family income.